{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:44:13Z","timestamp":1785437053555,"version":"3.56.0"},"reference-count":102,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["22-15-00169"],"award-info":[{"award-number":["22-15-00169"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]},{"award":["22-15-00169"],"award-info":[{"award-number":["22-15-00169"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>DNA double-strand breaks (DSBs), caused by various endogenous and exogenous factors, pose a significant threat to genomic stability. Several conserved repair pathways address DSBs, with homologous recombination (HR) being the only mechanism capable of accurately restoring the original DNA sequence. The BRCA1 gene plays a critical role in HR and is involved in maintaining genomic stability, cell cycle regulation, transcription, and tumor angiogenesis. Germline mutations in BRCA1 are strongly associated with increased risks of breast, ovarian, and other cancers. Dysfunction of BRCA1 leads to homologous recombination deficiency (HRD), forcing cells to rely on error-prone repair pathways, which promotes genomic instability and tumorigenesis. Besides hereditary mutations, HRD can also arise in sporadic cancers through epigenetic mechanisms such as promoter hypermethylation and reduced BRCA1 expression. Although BRCA1 deficiency is uncommon in lung cancer, BRCA1 status is considered a potential biomarker for sensitivity to platinum-based chemotherapy and other cytotoxic agents used in lung cancer treatment. However, the impact of BRCA1 on treatment response and prognosis in lung cancer remains controversial and not fully understood. This review summarizes current evidence on the role of BRCA1 in modulating chemotherapy response and disease outcomes in lung cancer patients, highlighting its potential as a biomarker for personalized therapy selection. Thus, in this context, the key unresolved issues critical for the development of personalized treatment strategies for lung cancer associated with BRCA1 alterations include the identification of molecular biomarkers most reliably associated with tumor sensitivity to chemotherapy. In addition, the development of methods for identifying patients with homologous recombination deficiency specifically in lung tumors appears to be of considerable importance, as does a better understanding of how the biological and therapeutic implications of BRCA1-related parameters in lung cancer differ from those observed in other tumor types. Addressing these challenges could substantially improve the efficacy of chemotherapy and patient outcomes, while also expanding the opportunities for a personalized approach to treatment selection in patients with lung cancer.<\/jats:p>","DOI":"10.3390\/ijms27146364","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:54:13Z","timestamp":1784534053000},"page":"6364","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BRCA1 Gene as a Potential Marker for Lung Cancer Therapy"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7419-4512","authenticated-orcid":false,"given":"Matvey M.","family":"Tsyganov","sequence":"first","affiliation":[{"name":"Department of Experimental Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634050 Tomsk, Russia"},{"name":"Biochemistry and Molecular Biology Division, Siberian State Medical University, 2 Moskovsky Trakt, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2716-3075","authenticated-orcid":false,"given":"Irina A.","family":"Tsydenova","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-920X","authenticated-orcid":false,"given":"Daria S.","family":"Dolgasheva","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina K.","family":"Ibragimova","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 5 Kooperativny Street, 634050 Tomsk, Russia"},{"name":"Biochemistry and Molecular Biology Division, Siberian State Medical University, 2 Moskovsky Trakt, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41580-020-0218-z","article-title":"The antitumorigenic roles of BRCA1\u2013BARD1 in DNA repair and replication","volume":"21","author":"Tarsounas","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","article-title":"How cells ensure correct repair of DNA double-strand breaks","volume":"293","author":"Her","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1101\/gad.14.8.927","article-title":"BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures","volume":"14","author":"Wang","year":"2000","journal-title":"Genes Dev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1038\/sj.onc.1204712","article-title":"BRCA1 and GADD45 mediated G2\/M cell cycle arrest in response to antimicrotubule agents","volume":"20","author":"Mullan","year":"2001","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1083\/jcb.200108049","article-title":"BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations","volume":"155","author":"Ye","year":"2001","journal-title":"J. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/cbt.5.2.2479","article-title":"Substrates of the BRCA1-dependent ubiquitin ligase","volume":"5","author":"Starita","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1073\/pnas.95.5.2302","article-title":"BRCA1 regulates p53-dependent gene expression","volume":"95","author":"Ouchi","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"36230","DOI":"10.1074\/jbc.M002539200","article-title":"BRCA1 physically and functionally interacts with ATF1","volume":"275","author":"Houvras","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1042\/BST0351342","article-title":"Role played by BRCA1 in transcriptional regulation in response to therapy","volume":"35","author":"Murray","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1046\/j.1365-2362.2003.01243.x","article-title":"Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: A comparison with VEGF and Flt-1","volume":"33","author":"Caine","year":"2003","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of\u2019BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/jrr\/rrw032","article-title":"Unsolved mystery: The role of BRCA1 in DNA end-joining","volume":"57","author":"Saha","year":"2016","journal-title":"J. Radiat. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.7939630","article-title":"BRCA1 mutations in primary breast and ovarian carcinomas","volume":"266","author":"Futreal","year":"1994","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/sj.onc.1207256","article-title":"Inactivation of the Fanconi anemia\/BRCA pathway in lung and oral cancers: Implications for treatment and survival","volume":"23","author":"Marsit","year":"2004","journal-title":"Oncogene"},{"key":"ref_20","first-page":"1728","article-title":"Prognostic significance of ERCC1, RRM1, TOP1, TOP2A, TYMS, TUBB3, GSTP1 and BRCA1 mRNA expressions in patients with non-small-cell lung cancer receiving a platinum-based chemotherapy","volume":"25","author":"Tsyganov","year":"2020","journal-title":"J. BUON"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Allingham-Hawkins, D., Lea, A., and Levine, S. (2010). ERCC1 expression analysis to guide therapy in non-small cell lung cancer. PLoS Curr., 2.","DOI":"10.1371\/currents.RRN1202"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/13993003.00359-2016","article-title":"Risk factors for lung cancer worldwide","volume":"48","author":"Malhotra","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4143\/crt.2017.119","article-title":"Interstitial lung disease and lung Cancer development: A 5-year Nationwide population-based study","volume":"50","author":"Choi","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.ejca.2012.01.038","article-title":"Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium","volume":"48","author":"Liu","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ng.254","article-title":"Lung cancer susceptibility locus at 5p15.33","volume":"40","author":"McKay","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature06885","article-title":"A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25","volume":"452","author":"Hung","year":"2008","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/JTO.0000000000000052","article-title":"Germline EGFR T790M mutation found in multiple members of a familial cohort","volume":"9","author":"Yu","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"djt338","DOI":"10.1093\/jnci\/djt338","article-title":"Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas","volume":"106","author":"Yamamoto","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ng.3002","article-title":"Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer","volume":"46","author":"Wang","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Pilarski","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ajhg.2014.12.016","article-title":"A recurrent mutation in PARK2 is associated with familial lung cancer","volume":"96","author":"Xiong","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2018.05.027","article-title":"Germline mutations in young non-smoking women with lung adenocarcinoma","volume":"122","author":"Donner","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.20892\/j.issn.2095-3941.2018.0506","article-title":"Prevalence and clinical significance of pathogenic germline BRCA1\/2 mutations in Chinese non-small cell lung cancer patients","volume":"16","author":"Hu","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","article-title":"Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L) 1 immune checkpoint inhibition in non\u2013small cell lung cancer","volume":"26","author":"Ricciuti","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.21037\/tlcr-19-403","article-title":"The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility","volume":"9","author":"Liu","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_36","first-page":"4989","article-title":"Whole exome sequencing reveals clinically important pathogenic mutations in DNA repair genes across lung cancer patients","volume":"13","author":"Wang","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1158\/0008-5472.CAN-09-2850","article-title":"Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination","volume":"70","author":"Ransburgh","year":"2010","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S963","DOI":"10.1016\/j.jtho.2019.08.2109","article-title":"EP1. 03-28 Frequency and Molecular Characteristics of BRCA1 Mutations in Non-Small Cell Lung Cancer from East Asian Patients","volume":"14","author":"Huang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jtho.2017.08.011","article-title":"Germline mutations in DNA repair genes in lung adenocarcinoma","volume":"12","author":"Parry","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-17-1582","article-title":"Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non\u2013small cell lung cancer","volume":"24","author":"Fan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jtho.2018.12.006","article-title":"EGFR and ERBB2 germline mutations in Chinese lung cancer patients and their roles in genetic susceptibility to cancer","volume":"14","author":"Lu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1900721","DOI":"10.1002\/advs.201900721","article-title":"Circulating DNA-based sequencing guided anlotinib therapy in non-small cell lung cancer","volume":"6","author":"Lu","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e13007","DOI":"10.1200\/JCO.2019.37.15_suppl.e13007","article-title":"BRCA1\/2 germline mutations and response to PARP inhibitor treatment in lung cancer","volume":"37","author":"Fang","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1002\/cam4.5148","article-title":"Mutational landscape of homologous recombination-related genes in small-cell lung cancer","volume":"12","author":"Wu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.onc.1209153","article-title":"DSS1 is required for the stability of BRCA2","volume":"25","author":"Li","year":"2006","journal-title":"Oncogene"},{"key":"ref_47","first-page":"S522","article-title":"P1.03-27 somatic mutations in BRCA2 genes are associated with prognosis in chinese non-small-cell lung cancer patients","volume":"13","author":"Lai","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2019.09.008","article-title":"Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization","volume":"137","author":"Kadouri","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_50","first-page":"100068","article-title":"Somatic and germline BRCA 1 and 2 mutations in advanced NSCLC from the SAFIR02-lung trial","volume":"1","author":"Remon","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41698-021-00199-8","article-title":"A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures","volume":"5","author":"Diossy","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e703","DOI":"10.1016\/j.cllc.2021.01.009","article-title":"Therapeutic Potential of Olaparib in Combination with Pembrolizumab in a Young Patient with a Maternally Inherited BRCA2 Germline Variant: A Research Report","volume":"22","author":"Waddington","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_53","first-page":"369","article-title":"The importance of BRCA1 and BRCA2 genes mutations in breast cancer development","volume":"30","author":"Mehrgou","year":"2016","journal-title":"Med. J. Islam. Repub. Iran"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"a006223","DOI":"10.1101\/mcs.a006223","article-title":"Case report: Olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant","volume":"8","author":"Hao","year":"2022","journal-title":"Mol. Case Stud."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.12998\/wjcc.v9.i25.7498","article-title":"Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report","volume":"9","author":"Zhang","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1097\/CAD.0000000000001160","article-title":"Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: A case report","volume":"33","author":"Wu","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1159\/000501304","article-title":"Somatic BRCA2 mutation-positive concurrent accessory male breast cancer (BC) and non-small cell lung cancer (NSCLC): Excellent efficacy of palbociclib, fulvestrant and leuprolide in platinum-exposed and endocrine-refractory BC associated with cyclin D1 and FGFR1 amplification and of carboplatin, paclitaxel and radiation in NSCLC","volume":"12","author":"Cheng","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/hmg\/ddh260","article-title":"BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer","volume":"13","author":"Taron","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Rosell, R., Perez-Roca, L., Sanchez, J.J., Cobo, M., Moran, T., Chaib, I., Provencio, M., Domine, M., Sala, M.A., and Jimenez, U. (2009). Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005133"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-9966-32-15","article-title":"Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum-and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: A system review and meta-analysis","volume":"32","author":"Yang","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1038\/sj.onc.1204812","article-title":"Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway","volume":"20","author":"Lafarge","year":"2001","journal-title":"Oncogene"},{"key":"ref_62","first-page":"6221","article-title":"BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis","volume":"63","author":"Quinn","year":"2003","journal-title":"Cancer Res."},{"key":"ref_63","first-page":"LBA8002","article-title":"Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656\/GECP-BREC)","volume":"31","author":"Moran","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/annonc\/mdu389","article-title":"Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies","volume":"25","author":"Moran","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Tsyganov, M.M., Rodionov, E.O., Ibragimova, M.K., Miller, S.V., Cheremisina, O.V., Frolova, I.G., Tuzikov, S.A., and Litviakov, N.V. (2022). Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2\u03b1, TUB\u03b23, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101647"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/JTO.0b013e318244bdd4","article-title":"ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer","volume":"7","author":"Papadaki","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1078-0432.CCR-05-2694","article-title":"Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non\u2013small cell lung cancer","volume":"13","author":"Lee","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/03936155221088882","article-title":"BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II\u2013IV non-small cell lung cancer: A meta-analysis","volume":"37","author":"Huang","year":"2022","journal-title":"Int. J. Biol. Markers"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"80869","DOI":"10.18632\/oncotarget.20715","article-title":"BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3892\/ol.2015.3894","article-title":"Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study","volume":"11","author":"Huang","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ng.159","article-title":"Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation","volume":"40","author":"Kondo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15592294.2016.1237345","article-title":"Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives","volume":"11","author":"Schiffmann","year":"2016","journal-title":"Epigenetics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4","article-title":"Loss of heterozygosity on chromosome 13q12\u2013q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors","volume":"92","author":"Gras","year":"2001","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1349-7006.2010.01568.x","article-title":"Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3\u2032-kinase\u2013Akt pathway","volume":"101","author":"Wang","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2010.12.011","article-title":"Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer","volume":"303","author":"Zhang","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/cncr.27754","article-title":"Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non\u2013small cell lung cancer","volume":"119","author":"Harada","year":"2013","journal-title":"Cancer"},{"key":"ref_77","first-page":"8544","article-title":"Prognostic significance of BRCA1 and RASSF1A promoter hypermethylation in non-small cell lung cancer patients","volume":"9","author":"Gao","year":"2016","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.prp.2019.01.032","article-title":"Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas","volume":"215","author":"Nguyen","year":"2019","journal-title":"Pathol.-Res. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4161\/cbt.22004","article-title":"Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma","volume":"13","author":"Valverde","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/cncr.23312","article-title":"Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray","volume":"112","author":"Wang","year":"2008","journal-title":"Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1038\/srep04186","article-title":"A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma","volume":"4","author":"Do","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-04-2378","article-title":"Methylation profiling of archived non\u2013small cell lung cancer: A promising prognostic system","volume":"11","author":"Safar","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"djw148","DOI":"10.1093\/jnci\/djw148","article-title":"Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer","volume":"108","author":"Kristel","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1038\/s41598-023-33932-3","article-title":"The genome-wide mutational consequences of DNA hypomethylation","volume":"13","author":"Besselink","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ccr.2006.02.016","article-title":"Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage","volume":"9","author":"Suzuki","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4161\/cam.4.1.10884","article-title":"Chromosomal and genomic changes in lung cancer","volume":"4","year":"2010","journal-title":"Cell Adhes. Migr."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.6274023","article-title":"Specific chromosome defect associated with human small-cell lung cancer: Deletion 3p (14\u201323)","volume":"215","author":"Lee","year":"1982","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1038\/sj.onc.1205836","article-title":"Chromosomal imbalances in human lung cancer","volume":"21","author":"Balsara","year":"2002","journal-title":"Oncogene"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ijc.21178","article-title":"Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer","volume":"117","author":"Tseng","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.molonc.2011.07.007","article-title":"p53: Guardian of ploidy","volume":"5","author":"Aylon","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.humpath.2018.10.004","article-title":"Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers","volume":"84","author":"Tian","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Tsyganov, M.M., Ibragimova, M.K., Garbukov, E.Y., Bragina, O.D., Karchevskaya, A.A., Usynin, E.A., and Litvyakov, N.V. (2022). Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010207"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/hmg\/ddi170","article-title":"Global gene expression as a function of germline genetic variation","volume":"14","author":"French","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/35101031","article-title":"Two genetic hits (more or less) to cancer","volume":"1","author":"Knudson","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability\u2014An evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc1714","article-title":"On the road to cancer: Aneuploidy and the mitotic checkpoint","volume":"5","author":"Kops","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2017.03.036","article-title":"Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers","volume":"397","author":"Sokolenko","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/ijc.32776","article-title":"Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors","volume":"146","author":"Sokolenko","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_99","first-page":"116","article-title":"Modulation of homologous recombination gene activity in breast tumor cells in an in vitro model","volume":"11","author":"Tsyganov","year":"2024","journal-title":"Uspekhi Mol. Onkol. = Adv. Mol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ijc.31898","article-title":"BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy","volume":"144","author":"Mio","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_102","first-page":"699","article-title":"Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations","volume":"12","author":"Medina","year":"2003","journal-title":"Cancer Epidemiol. Biomark. Prev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6364\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:25:24Z","timestamp":1784607924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":102,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146364"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146364","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}